ARICEPT

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Dementia With Parkinson's Disease

Conditions

Dementia With Parkinson's Disease

Trial Timeline

Aug 1, 2002 → Jul 1, 2005

NCT ID

NCT00165815

About ARICEPT

ARICEPT is a phase 3 stage product being developed by Eisai for Dementia With Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00165815. Target conditions include Dementia With Parkinson's Disease.

What happened to similar drugs?

7 of 20 similar drugs in Dementia With Parkinson's Disease were approved

Approved (7) Terminated (1) Active (12)

🔄[18F]NAV4694Navidea BiopharmaceuticalsPhase 3

❌AL001 + Placebo + Open label - AL001AlectorPhase 3

✅E2020 + PlaceboEisaiApproved

🔄donepezil hclEisaiPhase 3

🔄Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3

✅donepezil hydrochloride (Aricept)EisaiApproved

🔄E2020 + E2020EisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02158910	Pre-clinical	Completed	Mar 1, 2015	Jun 1, 2016	Alzheimer's Disease
NCT00230568	Approved	Completed	Dec 1, 2005	Dec 1, 2007	Alzheimer's Disease
NCT00103948	Phase 2	Completed	Feb 1, 2005	Feb 1, 2007	Cognitive Impairment
NCT00165815	Phase 3	Completed	Aug 1, 2002	Jul 1, 2005	Dementia With Parkinson's Disease

Competing Products

20 competing products in Dementia With Parkinson's Disease

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 3	26
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
Mecobalamin	Eisai	Approved	43
E2020 + Placebo	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43